{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:16:31Z","timestamp":1784906191788,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.juro.2008.09.006","type":"journal-article","created":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T01:17:10Z","timestamp":1229476630000},"page":"81-87","source":"Crossref","is-referenced-by-count":32,"title":["Neoadjuvant Platelet Derived Growth Factor Receptor Inhibitor Therapy Combined With Docetaxel and Androgen Ablation for High Risk Localized Prostate Cancer"],"prefix":"10.1097","volume":"181","author":[{"given":"Paul","family":"Mathew","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis L.","family":"Pisters","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas L.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Thall","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Horne","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol J.","family":"Oborn","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Langley","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaiah J.","family":"Fidler","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2008.09.006_bib1","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","article-title":"Mechanism of action and in vivo role of platelet-derived growth factor","volume":"79","author":"Heldin","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.juro.2008.09.006_bib2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jnci\/95.6.458","article-title":"Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases","volume":"95","author":"Uehara","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2008.09.006_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.juro.2008.09.006_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jnci\/djj211","article-title":"Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer","volume":"98","author":"Kim","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2008.09.006_bib5","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.1200\/JCO.2005.03.3068","article-title":"High-risk localized prostate cancer: a case for early chemotherapy","volume":"23","author":"Gleave","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2008.09.006_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urolonc.2006.03.005","article-title":"Neoadjuvant therapy before radical prostatectomy: where have we been?","volume":"25","author":"Pendleton","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2008.09.006_bib7","first-page":"3779","article-title":"STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake","volume":"9","author":"Pietras","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2008.09.006_bib8","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2008.09.006_bib9","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-07-1269","article-title":"Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases","volume":"13","author":"Mathew","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2008.09.006_bib10","unstructured":"Mathew P, Thall P, Wen S, Bucana C, Lin S et al: Platelet-derived growth factor (PDGF) receptor activation status, PDGF ligand kinetics and progression-free survival in men receiving docetaxel for castrate-resistant prostate cancer. Proceedings of the Genitourinary Cancers Symposium 2008; abstract 20246."},{"key":"10.1016\/j.juro.2008.09.006_bib11","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"60","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.juro.2008.09.006_bib12","first-page":"549","article-title":"Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas","volume":"7","author":"Fudge","year":"1994","journal-title":"Mod Pathol"},{"key":"10.1016\/j.juro.2008.09.006_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1535-6108(02)00030-2","article-title":"Gene expression correlates of clinical prostate cancer behavior","volume":"1","author":"Singh","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.juro.2008.09.006_bib14","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2004.10.116","article-title":"Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer","volume":"22","author":"Mathew","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2008.09.006_bib15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1464-410X.2007.06760.x","article-title":"Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer","volume":"100","author":"Prayer-Galetti","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2008.09.006_bib16","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2000.18.5.1050","article-title":"Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results","volume":"18","author":"Pettaway","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2008.09.006_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ju.0000108122.36893.5a","article-title":"Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I\/II study","volume":"171","author":"Konety","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.09.006_bib18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0090-4295(02)02519-0","article-title":"Neoadjuvant docetaxel and estramustine chemotherapy in high-risk\/locally advanced prostate cancer","volume":"61","author":"Hussain","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.juro.2008.09.006_bib19","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-05-0299","article-title":"Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer","volume":"11","author":"Febbo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2008.09.006_bib20","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.urology.2004.01.040","article-title":"Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer","volume":"63","author":"Dreicer","year":"2004","journal-title":"Urology"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534708024245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534708024245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2008.09.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:57:46Z","timestamp":1784905066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.juro.2008.09.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1016\/j.juro.2008.09.006"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2008.09.006","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}